Word abonnee en neem Beursduivel Premium
Rode planeet als pijlen grid met hoorntjes Beursduivel
Aandeel

Novacyt FR0010397232

Laatste koers (eur)

0,830
  • Verschill

    +0,080 +10,67%
  • Volume

    1.517.074 Gem. (3M) 170,3K
  • Bied

    -  
  • Laat

    -  
+ Toevoegen aan watchlist

Novacyt de volgende biotech raket!

70.358 Posts
Pagina: «« 1 ... 11 12 13 14 15 ... 3518 »» | Laatste | Omlaag ↓
  1. [verwijderd] 6 december 2018 13:56
    Novacyt (EURONEXT GROWTH: ALNOV; AIM: NCYT), an international specialist in clinical diagnostics, today announces it has received another substantial order for Primerdesign’s q16 molecular instruments from a new customer within the fast growing Chinese market. The order for 100 molecular diagnostic instruments has been paid in advance and takes the number of q16 instruments sold into the Asia Pacific region to over 230 units.
    The genesig® q16 is Primerdesign’s proprietary molecular testing instrument which is designed to make DNA testing affordable and easy to use. The latest order comes from a new distributor recently appointed by Novacyt and the instruments will be used in clinical diagnostic markets. This new customer provides Novacyt with a potential opportunity for further significant instrument, and genesig® reagent sales in 2019.
    Primerdesign has now sold over 450 q16 units since its launch in 2015. As instrument sales grow, the Company expects a pull-through effect in relation to repeat genesig® reagent sales. Reflecting this, year to date genesig® reagent sales have increased 35% versus the comparable period in 2017.

    Graham Mullis, Group CEO of Novacyt, commented:

    “I am very pleased to see this order from another new customer in China which helps to further reinforce our continued investment and success in the Asia Pacific region and provides additional opportunities for future instrument and reagent sales”.
  2. [verwijderd] 11 december 2018 11:33
    www.businesswire.com/news/home/201812...

    Novacyt Announces Update on Strategic Review of Non-Core Assets
    NOVAprep® and clinical laboratory enter formal sales process
    Novacyt to enhance focus on core profitable diagnostic products business

    The Board is optimistic about the current levels of interest and engagement in the sale of these two business units and expects to update shareholders on the sale processes in the first quarter of 2019
  3. kmmr 18 december 2018 19:25
    quote:

    SJURVM schreef op 11 december 2018 11:33:

    www.businesswire.com/news/home/201812...

    Novacyt Announces Update on Strategic Review of Non-Core Assets
    NOVAprep® and clinical laboratory enter formal sales process
    Novacyt to enhance focus on core profitable diagnostic products business

    The Board is optimistic about the current levels of interest and engagement in the sale of these two business units and expects to update shareholders on the sale processes in the first quarter of 2019
    Goed nieuws! Kan de koers straks weer richting de euro
  4. [verwijderd] 28 december 2018 09:56
    The Company estimates revenue from continuing operations, which will include
    the Primerdesign and Lab21 business units, of €13.7m to €14.4m, which compares
    to the market consensus of €15.85m.
    The shortfall in sales is primarily due to shipping of confirmed tender orders
    amounting to more than €1.0m slipping into the next financial period.

    novacyt.com/wp-content/uploads/2018/1...
  5. kmmr 3 januari 2019 19:34
    Ik het slot van de beurs vandaag gemist, maar wat is er gebeurd met Novacyt?
  6. [verwijderd] 13 februari 2019 13:18
    Still no sale of Novaprep and still needing €2m for cashflow purposes.

    It seems as if an institutional investor has also left the ship in the last few days.

    Touched a low yesterday. We need some news.
  7. [verwijderd] 21 februari 2019 16:50
    quote:

    SJURVM schreef op 13 februari 2019 13:18:

    Still no sale of Novaprep and still needing €2m for cashflow purposes.
    Only an analist is saying that.
    It seems reasonable.
    but the company never published that they are in need of capital.
  8. BP 23 februari 2019 17:12
    Dit zou geweldig zijn, nu sprokkelen en later oogsten

    Novacyt Sociétéonyme (EURONEXT: ALNOV) aandeel heeft 2% gepresteerd en is € 0,006 gewijzigd, terwijl de waarde van het aandeel bij de laatste handelssessie € 0,306 bedroeg. Op dit moment is de stock 52 week hoge prijs gelegen op 0.808 en 52 weken laag gelegen op 0.282. 620565 aandelen die op handen worden verhandeld, terwijl het een gemiddeld volume is met 320655 aandelen. De huidige consensusbeoordeling voor analisten klokt op 1 op bedrijfsaandelen. Analisten schatten dat aandelen een waarde zouden bereiken van € 1,25 in een periode van één jaar.
  9. [verwijderd] 26 februari 2019 20:35
    Ging weer lekker vandaag.
    Maar ja, niet raar, dit bedrijf heeft nog veel geld nodig.
    Binnenkort weer 3 miljoen.
    Zal net als de vorige keer wel weer een enorme aandelenuitgifte worden.

    Uit halfjaarverslag:

    As of 30 June 2018, the Group’s financing primarily comprised:

    - A bond subscribed by Kreos Capital V Ltd in the amount of €3,000,000 issued on 12 May 2016, with an interest rate of 12.5 % for a term of 3 years;

    - A convertible bond subscribed by Vatel in the amount of €1,500,000 issued on 31 March 2017, with an interest rate of 7.9 % for a term of 3 years;

    - A convertible bond subscribed by Vatel in the amount of €4,000,000 issued on 30 June 2018, with an interest rate of 7.4 % for a term of 3 years
  10. [verwijderd] 13 maart 2019 13:39
    February 26, 2019 02:00 AM Eastern Standard Time

    PARIS & CAMBERLEY, England--(BUSINESS WIRE)--Regulatory News:

    Novacyt (EURONEXT GROWTH: ALNOV; AIM: NCYT), an international specialist in clinical diagnostics, announces an update on its current position and funding plans. The Company confirms that 2019 trading has started positively and is in line with 2019 management expectations. The Company also continues to make progress with the ongoing negotiations in relation to the sale of the NOVAprep® and the Clinical Lab businesses and will continue to update the market as the transactions progress.

    The Company’s cash position as at 22 February 2019 was approximately €950,000 which is ahead of plan and the Company is currently in advanced discussions with debt providers in relation to a material investment of which a significant proportion will be used to consolidate our current debt obligations. The Company expects to complete this financing within the next six to eight weeks. Although there can be no guarantee in respect of the amount that can be raised, the preference of the Company is to target the raising of funds in the least dilutive form for shareholders. Further announcements will be made as appropriate in due course.
  11. wieweet 5 april 2019 20:23
    Afgelopen dagen even een zwikkie gekocht net onder de 0,24. Koers lijkt uitgebodemd...Yep aankomende 2 weken maar eens knallen.

    vrgr
  12. [verwijderd] 23 april 2019 15:25
    quote:

    Show_Me_The_Money schreef op 26 september 2018 09:23:

    ...................

    Als ik het goed zie 2 miljoen verlies in een half jaar en nog 2 miljoen in kas.
    Reken maar uit.
    Hopelijk komt er geen financiering a la Esperite of Visiomed uit de hoge hoed bij dit aandeel want dan gaat het ver naar beneden.

    Dus toch een equity line.
    Park Partners, "the investor".
    Die krijgen aandelen met korting en er is weinig fantasie nodig om te snappen wat ze daar mee gaan doen.
    Lees draadje Esperite, er zijn daar nog steeds mensen die denken dat Esgof een "investeerder" is.
    Tot overmaat van ramp ook nog warrants om het opwaarts potentieel de kop in te drukken.
    Voorlopig even afblijven.

  13. [verwijderd] 24 april 2019 13:36
    Needless to say that this latest convertible bond fund raising is not good news for existing shareholders. There will be a massive dilution which is already being priced in the latest drop in share price.
    Novacyt has already used €2m out of the €5m on offer

    As long as Novaprep which is leaking money is not sold I fear Novacyt will keep using the facility

    www.businesswire.com/news/home/201904...
70.358 Posts
Pagina: «« 1 ... 11 12 13 14 15 ... 3518 »» | Laatste |Omhoog ↑

Neem deel aan de discussie

Word nu gratis lid van Beursduivel.be

Al abonnee? Log in
Premium

Benieuwd naar onze analyses en kooptips?

Word nu abonnee van BeursDuivel en krijg onbeperkt toegang tot onze (koop)tips en succesvolle modelportefeuilles. Nu 3 maanden voor slechts €19,95! Profiteer van 55% korting!

Macro & Bedrijfsagenda

  1. 22 april

    1. NL investeringen februari
    2. SAP Q1-cijfers
    3. NL consumentenvertrouwen april
    4. NL prijzen bestaande koopwoningen maart
    5. ING jaarvergadering
    6. VS Chicago Fed-index maart
    7. EU consumentenvertrouwen april (voorlopig)
  2. 23 april

    1. Japan samengestelde inkoopmanagersindex april
    2. Novartis Q1-cijfers
    3. Renault Q1-cijfers
de volitaliteit verwacht indicator betekend: Market moving event/hoge(re) volatiliteit verwacht